Cheng Yi | Oncology | Best Researcher Award

Published on by Academic Awards

Mr. Cheng Yi | Oncology | Best Researcher Award

West China Hospital of Sichuan University | China

Mr. Cheng Yi, a distinguished Medical Doctor from Sichuan, currently serves as a professor and doctoral supervisor at the Cancer Center of West China Hospital, Sichuan University, and as an adjunct doctoral supervisor at Chengdu University of Traditional Chinese Medicine. He earned his Bachelor and Master of Medicine from Xi’an Jiaotong University, his Doctor of Medicine from Fudan University, and completed postdoctoral research at the University of Toronto. Since 1996, he has been deeply engaged in oncology clinical practice, scientific research, and teaching, advancing to professor and chief physician in 2006. His academic roles include standing committee and deputy director positions across multiple Chinese medical associations, reflecting his leadership in oncology and integrative medicine. With 138 publications, over 2,422 citations, and an h-index of 26, his research spans nanomedicine, cancer therapeutics, molecular oncology, immunotherapy, and systematic reviews, with impactful studies published in Journal of Materials Chemistry B, Nano Research, Frontiers in Oncology, PLoS One, and Journal of Cancer Research and Clinical Oncology. His international experience and consistent contributions to cancer treatment innovation highlight his strong candidacy for the Best Researcher Award, showcasing excellence in scientific impact, academic mentorship, and translational oncology research.

Profile: Scopus | Orcid

Featured Publications

Zhang, L.-N., Wei, Y.-F., Ran, X.-Y., Shi, L., Wang, Z.-Y., Chen, S.-Y., Yi, C., Yu, X.-Q., & Li, K. (2025). Liberating exciton transfer as a pioneering strategy to construct type I photosensitizers for hypoxia deep-seated metastases suppression. JACS Au. Advance online publication.

Tan, S., Feng, M., Zhou, N., Zhang, S., Yi, C., & Gou, H. (2025). DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer. Cancer. Advance online publication.

Chen, P., Hou, W., Li, C., Liang, Q., Ma, L., Zhao, X., & Yi, C. (2025). Lived experiences of patients with advanced pancreatic cancer on patient-reported outcomes (PROs) management: A qualitative phenomenological study in Southwest China. BMJ Open, 15(1), e084259.

Ran, X.-Y., Xia, W.-L., Zhang, L.-N., Yu, X.-Q., Chen, P., Xie, K.-P., Zhao, Y., Yi, C., & Li, K. (2024). De novo design of type-I photosensitizer agents based on structure-inherent low triplet energy for hypoxia photodynamic therapy. Materials Horizons. Advance online publication.

Tan, S., Zhang, S., Zhou, N., Cai, X., Yi, C., & Gou, H. (2023). Efficacy and safety of fruquintinib dose-escalation strategy for elderly patients with refractory metastatic colorectal cancer: A single-arm, multicenter, phase II study. Cancer Medicine, 13(1), e6786.

Wei, Y., Zheng, L., Yang, X., Luo, Y., Yi, C., & Gou, H. (2023). Identification of immune subtypes and candidate mRNA vaccine antigens in small cell lung cancer. The Oncologist, 28(11), oyad193.

Tianzhu Qiu | Oncology | Women Researcher Award

Published on by Academic Awards

Prof. Dr. Tianzhu Qiu | Oncology | Women Researcher Award

Prof. Dr. Tianzhu Qiu, the First Affiliated Hospital with Nanjing Medical University, China

Prof. Dr. Tianzhu Qiu is an esteemed oncology expert with a Ph.D. in Medicine from Nanjing Medical University. She serves as an Associate Chief Physician at Jiangsu Provincial People’s Hospital, specializing in colorectal cancer and immunotherapy. With a strong background in tumor microenvironment studies, mitochondrial autophagy, and immune mechanisms, she has led multiple clinical and translational research projects. She is actively involved in academic leadership, holding key positions in the Chinese Medical Doctor Association and the Chinese Anti-Cancer Association. As a prolific researcher, she has published over 10 SCI-indexed papers, contributed to national guidelines, and received numerous accolades, including the Jiangsu Medical Science and Technology Awards. Dr. Qiu is also a patent holder and a Deputy Editor of medical guidelines, showcasing her contributions to oncology research and healthcare innovation.

Publication Profile

Scopus

Education 🎓

Prof. Dr. Tianzhu Qiu earned her Ph.D. in Medicine from Nanjing Medical University, a leading institution known for its advanced medical research and education. Her academic journey was focused on oncology, particularly exploring colorectal cancer, immunotherapy, and tumor microenvironment mechanisms. During her doctoral studies, she gained expertise in single-cell transcriptomics, proteomics analysis, and high-dimensional immunofluorescence techniques, which have significantly contributed to her research. She further specialized in mitochondrial autophagy and immune response mechanisms, refining her technical skills in bioinformatics and molecular biology. Her Ph.D. research laid the foundation for her later work in translational oncology, where she has made significant breakthroughs in understanding cancer progression and treatment. Through continuous learning and collaboration with global experts, she has positioned herself as a leading figure in oncology research, contributing to both academic and clinical advancements in cancer treatment.

Experience 🏥

Dr. Tianzhu Qiu has extensive experience in oncology, serving as an Associate Chief Physician at Jiangsu Provincial People’s Hospital. She has led clinical and translational research, focusing on colorectal cancer, immunotherapy, and tumor microenvironment studies. Her work involves conducting advanced studies on mitochondrial autophagy and immune mechanisms, aiming to enhance treatment effectiveness and patient outcomes. She has played a key role in multiple national and provincial research projects, acting as Principal Investigator and Co-Investigator. Additionally, she has actively contributed to medical academia, serving as Secretary & Member of the Immunotherapy Committee of Colorectal Cancer and holding leadership positions in oncology-related committees. Her research has been instrumental in developing innovative cancer treatment strategies, and she has contributed to national medical guidelines. Through her experience, Dr. Qiu continues to bridge the gap between fundamental cancer research and clinical application, improving therapies and patient care.

Awards & Honors 🏆

Dr. Tianzhu Qiu has been recognized for her outstanding contributions to oncology with prestigious awards. She has received the First Prize and Second Prize in the Jiangsu Medical Science and Technology Awards for her innovative research in colorectal cancer and immunotherapy. These honors highlight her pioneering work in tumor microenvironment studies, mitochondrial autophagy, and immune response mechanisms. Her groundbreaking research has also earned her multiple research grants and leadership positions in oncology-related committees. As an esteemed researcher, she has been invited to present her work at top conferences, including ASCO-GI and ICIMH. Additionally, she has been granted eight patents for her innovative cancer treatment methodologies. Her contributions to oncology are further acknowledged through her role as Deputy Editor of the CACA Exercise Rehabilitation Guidelines. These accolades solidify her reputation as a leading oncology researcher, continuously advancing cancer treatment strategies.

Research Focus 🔬

Dr. Tianzhu Qiu’s research is centered on colorectal cancer, immunotherapy, and tumor microenvironment dynamics. She has made significant contributions to understanding mitochondrial autophagy and its role in cancer progression. Her work also involves single-cell transcriptomics and proteomics analysis, helping to uncover novel biomarkers and therapeutic targets. Utilizing advanced techniques such as multiplex immunofluorescence and high-dimensional bioinformatics, she has developed new approaches for cancer diagnosis and treatment. Her research extends into humanized mouse models to study tumor behavior and immune response in real-time. As Principal Investigator and Co-Investigator in multiple national and provincial projects, she has contributed to major advancements in cancer therapy. Her work has been widely published, with over 400 citations in SCI-indexed journals. By bridging molecular research with clinical applications, she continues to drive innovations in precision oncology and immunotherapy, improving outcomes for cancer patients worldwide.

 

Publication Top Notes

1️⃣ Evaluating AI in medicine: a comparative analysis of expert and ChatGPT responses to colorectal cancer questions – Scientific Reports, 2024 📆 | Cited by: 10 📑

2️⃣ Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): An open-label, single-arm, phase 2 trial – Journal for ImmunoTherapy of Cancer, 2023 📆 | Cited by: 42 📑

Conclusion

Prof. Dr. Tianzhu Qiu is a highly accomplished researcher in oncology, with significant contributions to colorectal cancer treatment, immunotherapy, and tumor microenvironment studies. Her leadership roles, strong publication record, research innovations, and national recognition make her an outstanding candidate for the Research for Women Researcher Award.

Roger KoggeEnang | Soil Science | Best Researcher Award

Published on by Academic Awards

Dr. Roger Kogge Enang | Soil Science | Best Researcher Award

Dr. Gabriel Espinosa Carrasco, University of Dschang, Cameroon

Dr. Roger Kogge Enang is a strong candidate for the Best Researcher Award due to his extensive background and contributions in soil science and environmental research. Here’s why he stands out:

Publication profile

Orcid

Extensive Research Output:

Since 2016, Dr. Enang has been actively publishing, with at least two scientific articles per year. His research spans various critical areas in soil science, including soil classification, nutrient cycling, and pollution remediation.

Educational Background:

He holds a Ph.D. and MSc in Soil Science, and a BSc in Chemistry, with a specialization in environmental chemistry and soil fertility. His academic credentials underpin his solid research foundation.

Diverse Research Interests:

His research covers vital topics such as soil mineralogy, soil organic matter, and digital soil mapping. He has contributed significantly to understanding soil properties and their implications for agriculture and environmental management.

Professional Involvement:

Dr. Enang is an active member of several professional organizations, including the Cameroon Soil Science Society and the International Network on Soil Pollution. His roles in these organizations reflect his commitment to advancing the field.

Field and Laboratory Experience:

His practical experience includes extensive soil surveys, experimental design, and advanced laboratory analyses. This hands-on expertise enhances the applicability and impact of his research findings.

Notable Publications:

Dr. Enang has published numerous peer-reviewed articles in reputable journals, demonstrating his ability to contribute valuable knowledge to the scientific community.

Given his track record of impactful research, extensive publications, and professional dedication, Dr. Roger Kogge Enang is highly suitable for the Best Researcher Award.

 

Ken Kato | Oncology Award | Excellence in Research

Published on by Academic Awards

Dr. Ken Kato | Oncology Award | Excellence in Research

Dr. Ken Kato, National Cancer Center Hospital, Japan

Dr. Ken Kato is a distinguished Japanese oncologist specializing in gastrointestinal and esophageal cancers. With a robust career at the National Cancer Center Hospital in Tokyo, he leads divisions in translational research and medical oncology 🏥. Holding both an M.D. and a Ph.D. from prestigious institutions 🎓, Dr. Kato has a notable presence in clinical and research domains, with expertise in molecular targets and immunotherapy for cancer 🧬. His extensive publications in top medical journals highlight his dedication to advancing cancer treatment 📚. Dr. Kato is also an active member of several professional societies worldwide 🌏.

Publication profile

Scopus

Education

Dr. Kato earned his Ph.D. from Kyushu University in 2001 and his M.D. in 1995. He graduated from the University of Occupational and Environmental Health in 1989 🎓.

Research Focus

Dr. Ken Kato is a leading researcher in gastrointestinal and esophageal cancers, focusing primarily on early detection, treatment, and the molecular mechanisms of these malignancies 🧬. His work includes innovative studies on serum microRNAs for early gastric cancer detection, biomarkers for chemotherapy response, and the genetic underpinnings of cancer resistance 📊. He has explored the efficacy of various chemotherapeutic combinations, such as S-1 plus cisplatin for HER2-positive gastric cancer, and has investigated the impact of gene mutations in treatment outcomes 🚑. Dr. Kato’s research aims to advance precision medicine in oncology, improving patient survival and treatment efficacy 🌟.

Publication Top Notes

  • A novel combination of serum microRNAs for the detection of early gastric cancer – Abe, S., Matsuzaki, J., Sudo, K., … Saito, Y., Ochiya, T. Gastroenterological Endoscopy, 2021, 63(6), pp. 1310 📅, Cited by: 0 🔍
  • ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy – Takahashi, T., Yamahsita, S., Matsuda, Y., … Nagino, M., Ushijima, T. Journal of Cancer Research and Clinical Oncology, 2015, 141(3), pp. 453–463 📅, Cited by: 21 📊
  • Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer – Honma, Y., Shimada, Y., Takashima, A., … Sekine, S., Kushima, R. International Journal of Clinical Oncology, 2014, 19(5), pp. 863–870 📅, Cited by: 3 📈
  • Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer – Takahashi, N., Yamada, Y., Taniguchi, H., … Hamaguchi, T., Shimada, Y. BMC Research Notes, 2014, 7(1), 271 📅, Cited by: 41 🔬
  • Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection – Shoji, H., Yamada, Y., Taniguchi, H., … Hamaguchi, T., Shimada, Y. Cancer Science, 2014, 105(8), pp. 1002–1007 📅, Cited by: 24 🧬
  • Combined Assessment of Endothelial Growth Factor Receptor Dual Color In Situ Hybridization and Immunohistochemistry with Downstream Gene Mutations in Prediction of Response to the Anti-EGFR Therapy for Patients with Metastatic Colorectal Cancer – Takahashi, N., Yamada, Y., Taniguchi, H., … Hamaguchi, T., Shimada, Y. Archives of Medical Research, 2014, 45(5), pp. 366–374 📅, Cited by: 7 🔍
  • A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI) – Kato, K., Muro, K., Ando, N., … Nagai, K., Kato, H. Esophagus, 2014, 11(3), pp. 183–188 📅, Cited by: 30 🩺
  • Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: Combined analysis of the Japan Clinical Oncology Group Trials JCOG9205 and JCOG9912 – Takashima, A., Boku, N., Kato, K., … Shimada, Y., Ohtsu, A. Gastric Cancer, 2014, 17(3), pp. 522–528 📅, Cited by: 26 📊
  • Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma – Hayashi, H., Arao, T., Matsumoto, K., … Nishio, K., Yamada, Y. Oncotarget, 2014, 5(9), pp. 2588–2595 📅, Cited by: 33 🧪
  • Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer – Makazu, M., Kato, K., Takisawa, H., … Yamada, Y., Shimada, Y. Diseases of the Esophagus, 2014, 27(1), pp. 42–49 📅, Cited by: 31 🩹